MCCQE1 practice questions: prenatal care and screening under the SOGC guidelines

Three full clinical vignettes with worked explanations. Two of the three test numbers where Canadian practice has quietly separated from the sources most candidates revise from: the week group B streptococcus is swabbed, and the folic acid dose for an ordinary pregnancy.

Written by MCCQE1 Tutor editorial team, AYRIQ Technologies · Updated 16 November 2026

These are free samples. The full platform builds papers from the Canadian guidelines, grades them, and tracks every topic you get wrong.

Three numbers worth getting right

Routine prenatal care is mostly a schedule, and schedules are examinable. The three below are chosen because each one is commonly answered with a figure from the wrong country or the wrong decade.

The schedule points this page tests

Group B streptococcus Universal culture screening at 35 to 37 weeks under SOGC Guideline No. 298. Note the technique, because it is examinable in its own right: one swab, taken first from the vagina and then from the rectum through the anal sphincter — not two separate swabs, and not a vaginal swab alone. Re-screening is usual in practice if more than about five weeks elapse before delivery. The United States moved to 36 to 37+6 weeks; Canada did not, and that one-week difference is the whole question.
Rh immunoglobulin 300 µg anti-D at 28 weeks to every Rh-negative, non-sensitised pregnant woman where the fetus is Rh D-positive or of unknown type. The alternative is two doses of 120 µg at 28 and 34 weeks — 120 µg being the lowest dose currently available in Canada. An antibody screen is repeated before the dose is given. The current document is SOGC Guideline No. 448 (2024), which replaced Guideline No. 133; No. 133 gave the alternative schedule as 100–120 µg, so older revision notes carry a dose range the current guideline does not.
Folic acid The routine dose is 0.4 mg daily in a multivitamin, started before conception and continued through pregnancy and breastfeeding. A higher dose, commonly quoted as 4 to 5 mg daily, belongs to a defined higher-risk group — and that group is wider than most revision notes suggest. SOGC lists: a previous pregnancy affected by a neural tube defect; a family history of neural tube defects; pre-existing diabetes; obesity; medications that interfere with folate metabolism, such as certain antiepileptics; and malabsorption conditions.

A caution about this row, written deliberately. SOGC Guideline No. 427 is behind a publisher paywall, and we have not been able to read its recommendation table directly. The routine 0.4 mg dose and the higher-risk list above come from SOGC's own public summary and from Health Canada, and they agree. What we could not verify is whether the guideline uses two dose tiers or three: at least one published evidence summary describes an intermediate tier of 1.0 mg daily for moderate risk, sitting between 0.4 mg and 4–5 mg. Health Canada's public advice tells patients not to exceed 1 mg daily without speaking to a clinician. Treat the 0.4 mg routine dose as solid, and check the tiers in the guideline itself before relying on the high-dose figure clinically.

Three practice questions

Question 1 · Group B streptococcus timing

A 28-year-old woman in her second pregnancy attends a routine antenatal visit at 34 weeks' gestation. The pregnancy has been uncomplicated, she has no history of a previous infant with invasive group B streptococcal disease, and she has had no group B streptococcal bacteriuria in this pregnancy. She asks when she will be tested for group B streptococcus. Following the SOGC guideline, when should the vaginal and rectal swab be collected?

Show the answer and explanation

Correct answer: B. Between 35 and 37 weeks

The SOGC guideline screens by vaginal and rectal swab at 35 to 37 weeks. The window exists because colonisation comes and goes: a swab taken too early stops predicting the status at delivery, and a swab taken too late may not return in time to guide intrapartum management. If more than roughly five weeks pass between the swab and delivery, it is repeated.

Option C is the trap, and it is a good one, because it is not a made-up number. It is the American window, which moved to 36 to 37 weeks and 6 days. Canada did not follow. A candidate revising from American material will recognise 36–37+6 as authoritative, which is exactly what makes it dangerous.

Two situations in the stem were excluded for a reason: a previous infant with invasive group B streptococcal disease, and group B streptococcal bacteriuria in this pregnancy. Either of those means intrapartum prophylaxis regardless of the swab, so the swab stops being the thing that decides management.

Why the other options are wrong

  • A. 34 weeks is before the window. The result would be less predictive of her colonisation status when she actually delivers, which is the only thing the test is for.
  • C. This is the current United States timing, not the Canadian one. Knowing it is useful; applying it to a Canadian question is a wrong answer.
  • D. Routine screening in Canada is an antenatal culture, not a rapid test in labour. Intrapartum testing is not the standard pathway for a woman attending regular antenatal care.
  • E. Canadian practice is universal culture-based screening, not a risk-factor-only approach. Most women who deliver a colonised infant have no risk factors at all, which is why the risk-based strategy was abandoned.
Guideline anchor: SOGC guideline on the prevention of early-onset neonatal group B streptococcal disease: universal vaginal and rectal culture screening at 35 to 37 weeks, with intrapartum antibiotic prophylaxis for those who screen positive and for defined risk groups irrespective of the swab.
Question 2 · Rh immunoglobulin

A 24-year-old woman in her first pregnancy is blood group O negative. Her antibody screen at booking was negative, and a repeat antibody screen is negative. The father's blood group is unknown. She is now 28 weeks' gestation, the pregnancy has been uncomplicated, and she has had no bleeding, trauma or invasive procedure. Which of the following is the most appropriate management?

Show the answer and explanation

Correct answer: A. Give 300 µg of anti-D immunoglobulin now

Routine antenatal prophylaxis is given at 28 weeks, as a 300 µg dose of anti-D immunoglobulin, to every Rh-negative non-sensitised woman whose fetus is Rh-positive or of unknown type. Her negative antibody screen is not a reason to withhold it — it is the reason to give it. Prophylaxis prevents sensitisation; once she has antibodies, the opportunity has passed and anti-D no longer helps.

That is the conceptual trap in this question. Candidates read "not sensitised" as "does not need it", when the logic runs the other way.

An alternative schedule of two 100–120 µg doses at 28 and 34 weeks is recognised, with 120 µg the smallest dose available in Canada. A postpartum dose still follows if the infant proves Rh-positive, and additional doses are given for sensitising events such as bleeding, trauma, or an invasive procedure — none of which she has had.

Why the other options are wrong

  • B. This reverses the purpose of prophylaxis. Anti-D is given because she is not yet sensitised; a sensitised woman is the failure this programme exists to prevent.
  • C. Postpartum anti-D alone leaves the third trimester unprotected, which is when silent fetomaternal haemorrhage most often causes sensitisation. The postpartum dose is additional to the 28-week dose, not a substitute for it.
  • D. Paternity is not a safe basis for withholding prophylaxis, and in practice the father is often unavailable or his group unknown. Where fetal Rh type is unknown, prophylaxis is given.
  • E. Waiting for demonstrated fetomaternal haemorrhage misses the small, undetected bleeds that cause most sensitisation. Routine prophylaxis is not event-driven.
Guideline anchor: SOGC guidance on the prevention of Rh alloimmunisation: 300 µg anti-D immunoglobulin routinely at 28 weeks for Rh-negative non-sensitised women where the fetus is Rh-positive or of unknown type; alternatively two doses of 100 to 120 µg at 28 and 34 weeks.
Question 3 · Folic acid dosing

A 30-year-old woman is planning a pregnancy. She is healthy, takes no medication, has no malabsorptive condition, is not obese and does not have diabetes or epilepsy. She has had no previous pregnancy affected by a neural tube defect, has no personal history of one, and no first-degree relative has had one. She asks what dose of folic acid she should take. Following current SOGC guidance, which of the following is most appropriate?

Show the answer and explanation

Correct answer: A. 0.4 mg daily in a multivitamin, continued through pregnancy and breastfeeding

Current SOGC guidance is 0.4 mg of folic acid daily, in a multivitamin formulation, for all pregnant women regardless of their risk, continued through pregnancy and breastfeeding. The multivitamin part is deliberate: the guidance is for a multivitamin containing folic acid, not for folic acid taken alone.

High-dose supplementation, commonly quoted as 4 to 5 mg daily, is reserved for women at genuinely higher risk of a folic-acid-sensitive anomaly. That group is wider than the neural tube defect history most candidates remember: SOGC also lists pre-existing diabetes, obesity, folate-interfering medications such as certain antiepileptics, and malabsorption conditions. Read the stem again and you will see it excludes every one of them, one by one — no malabsorptive condition, not obese, no diabetes, no epilepsy, no affected pregnancy, no personal history, no first-degree relative. A stem that works that hard to empty a list is telling you which arm of the recommendation applies.

The reason this question catches people is that "4 mg" is strongly associated with pregnancy in most candidates' memories, and older guidance used a 0.4 to 1.0 mg range for low risk. Giving every woman the high-risk dose is not a harmless excess of caution; it is the wrong answer to the question that was asked.

Why the other options are wrong

  • B. 4 mg is the high-risk dose. Nothing in her history places her in that group, and the stem went out of its way to exclude the conditions that would.
  • C. 5 mg sits at the top of the high-risk range and has the same problem as B, applied for longer.
  • D. Flour fortification reduced neural tube defects across Canada but did not remove the recommendation to supplement. Diet alone is not the guidance.
  • E. This invents a schedule. Neural tube closure is complete early in the first trimester, so escalating a dose in the second trimester would be too late to serve the purpose anyway.
Guideline anchor: SOGC Guideline No. 427, folic acid and multivitamin supplementation, as summarised by SOGC and by Health Canada: a daily multivitamin containing 0.4 mg of folic acid before conception and through pregnancy and breastfeeding, with a higher dose for defined higher-risk groups. We could not read the guideline's own dose table, which is paywalled; some summaries describe an intermediate 1.0 mg tier. Confirm the exact tiers in the guideline before applying the high dose.

Three traps this topic sets

1. The American GBS week. 36 to 37+6 is the United States window. Canada swabs at 35 to 37 weeks. Both numbers are real; only one answers a Canadian question.

2. Reading "not sensitised" as "does not need anti-D". Prophylaxis is for the unsensitised woman. The sensitised one is the outcome it exists to prevent.

3. Giving everyone 4 mg of folic acid. The routine dose is 0.4 mg in a multivitamin. The high dose belongs to a defined higher-risk group — which includes pre-existing diabetes, obesity, folate-interfering medication and malabsorption, not only a neural tube defect history. A stem that carefully excludes every one of those features is telling you which arm applies.

Sources

Every figure on this page is traceable to one of these. Guidelines are revised — open the source before you commit a number to memory.

  1. SOGC — clinical practice guidelines — the issuing body; check here for the current version of any guideline below
  2. The Prevention of Early-Onset Neonatal Group B Streptococcal Disease (JOGC, PDF) — universal screening at 35 to 37 weeks and the intrapartum prophylaxis criteria
  3. SOGC Guideline No. 448 — Prevention of Rh D Alloimmunization (2024) — the current guideline: 300 micrograms at 28 weeks, or two doses of 120 micrograms at 28 and 34 weeks
  4. SOGC Guideline No. 427 — Folic Acid and Multivitamin Supplementation — the guideline itself (paywalled: we could not read its dose table)
  5. SOGC — Preconception health and nutrition (public summary) — the 0.4 mg routine dose and SOGC's own list of higher-dose groups
  6. Health Canada — Folic acid and pregnancy — the 0.4 mg recommendation, and the advice not to exceed 1 mg daily without clinical guidance
  7. Ontario midwives — Group B Streptococcus clinical practice guideline (PDF) — the screening window and the five-week re-screening rule in practice

More free MCCQE1 practice questions

See all free MCCQE1 practice topics →

About these practice pages

MCCQE1 Tutor is a Canadian-guideline preparation platform for the Medical Council of Canada Qualifying Examination Part 1, built by AYRIQ Technologies. The questions on this page were written for this page and are given away free. They are not drawn from the subscriber question bank, so working through them uses up nothing you have paid for.

Practising on Canadian numbers is the whole point. Everything here is free; the platform is where it becomes a study plan.